Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
It's not hard to see why investors may be bullish on Recursion's business when you hear its CEO hype up its potential. Last year, CEO Chris Gibson wasn't holding back on the savings he believed the ...
SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する